ERBB2 and breast cancer: In the CLEOPATRA trial (a randomized phase III study in metastatic HER2+ BC receiving trastuzumab plus docetaxel with or without pertuzumab as first-line treatment), Baselga et al. showed that wild-type PIK3CA status was associated with a better prognosis, independently from the treatment effect.